Literature DB >> 23566964

Should all cases of lung cancer be presented at Tumor Board Conferences?

Marc Riquet1, Pierre Mordant, Mehdi Henni, Delphine Wermert, Elizabeth Fabre-Guillevin, Aurélie Cazes, Françoise Le Pimpec Barthes.   

Abstract

Tumor Board Conferences (TBCs) have been associated with higher adherence of staging and treatment to guidelines. The influence of TBCs on the rate of curative treatments has been established. Patients with lung nodules and tumors of unknown histology should not be presented before surgery, but every patient with malignant histology should be declared to the TBC coordinator and registered at the time of histologic confirmation. This approach allows physicians to deal rapidly with simple cases on a systematic basis, to give more attention to the most complicated situations, and to offer every patient the benefit of a multidisciplinary approach.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23566964     DOI: 10.1016/j.thorsurg.2013.01.003

Source DB:  PubMed          Journal:  Thorac Surg Clin            Impact factor:   1.750


  5 in total

1.  Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: an observational study.

Authors:  David G Brauer; Matthew S Strand; Dominic E Sanford; Vladimir M Kushnir; Kian-Huat Lim; Daniel K Mullady; Benjamin R Tan; Andrea Wang-Gillam; Ashley E Morton; Marianna B Ruzinova; Parag J Parikh; Vamsi R Narra; Kathryn J Fowler; Majella B Doyle; William C Chapman; Steven S Strasberg; William G Hawkins; Ryan C Fields
Journal:  HPB (Oxford)       Date:  2016-12-01       Impact factor: 3.647

Review 2.  The Benefit of a Multidisciplinary Approach to the Patient Treated with (Chemo) Radiation for Head and Neck Cancer.

Authors:  Paolo Bossi; Salvatore Alfieri
Journal:  Curr Treat Options Oncol       Date:  2016-10

Review 3.  Benefits and Limitations of a Multidisciplinary Approach in Cancer Patient Management.

Authors:  Rossana Berardi; Francesca Morgese; Silvia Rinaldi; Mariangela Torniai; Giulia Mentrasti; Laura Scortichini; Riccardo Giampieri
Journal:  Cancer Manag Res       Date:  2020-09-30       Impact factor: 3.989

4.  Evolution of induction chemotherapy for non-small cell lung cancer over the last 30 years: A surgical appraisal.

Authors:  Elizabeth Fabre; Caroline Rivera; Pierre Mordant; Laure Gibault; Antoine Dujon; Christophe Foucault; Françoise Le Pimpec-Barthes; Marc Riquet
Journal:  Thorac Cancer       Date:  2015-05-12       Impact factor: 3.500

5.  Pre-diagnosis Multidisciplinary Tumor Board and Time to Staging in Lung Cancer: The Case Western MetroHealth Experience.

Authors:  Prashanth Thalanayar Muthukrishnan; Maya Ratnam; Minh-Tri Nguyen; Michael Le; Douglas Gunzler; Debora Bruno; Michael Infeld
Journal:  Cureus       Date:  2020-01-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.